T. Rowe Price Associates’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
|
|||||
|
2023
Q4 | $2.24M | Sell |
|
|||||
|
2023
Q3 | $106M | Buy |
|
|||||
|
2023
Q2 | $64.2M | Buy |
|
|||||
|
2023
Q1 | $65.8M | Buy |
|
|||||
|
2022
Q4 | $64.2M | Buy |
|
|||||
|
2022
Q3 | $79.8M | Buy |
|
|||||
|
2022
Q2 | $70.6M | Sell |
|
|||||
|
2022
Q1 | $135M | Sell |
|
|||||
|
2021
Q4 | $319M | Buy |
|
|||||
|
2021
Q3 | $374M | Buy |
|
|||||
|
2021
Q2 | $310M | Buy |
|
|||||
|
2021
Q1 | $263M | Sell |
|
|||||
|
2020
Q4 | $343M | Buy |
|
|||||
|
2020
Q3 | $218M | Buy |
|
|||||
|
2020
Q2 | $149M | Buy |
|
|||||
|
2020
Q1 | $99M | Sell |
|
|||||
|
2019
Q4 | $179M | Buy |
|
|||||
|
2019
Q3 | $104M | Buy |
|
|||||
|
2019
Q2 | $124M | Buy |
|
|||||
|
2019
Q1 | $59.9M | Buy |
|
|||||
|
2018
Q4 | $14M | Buy |
|
|||||
|
2018
Q3 | $15.4M | Buy |
|
|||||
|
2018
Q2 | $10.5M | Buy |
|
|||||
|
2018
Q1 | $5.72M | Buy |
|